US 12,031,137 B2
Compositions comprising SASP modulators and senescence attenuators and uses thereof for modulating cellular senescence
Przemyslaw Sapieha, Beaconsfield (CA); Frédérick Antoine Mallette, Montreal (CA); Malika Oubaha, Montreal (CA); Normand Beaulieu, Montreal (CA); and Ariel Wilson, Montreal (CA)
Assigned to RSEM, LIMITED PARTNERSHIP, Montreal (CA)
Filed by RSEM, LIMITED PARTNERSHIP, Montreal (CA)
Filed on Apr. 23, 2021, as Appl. No. 17/302,113.
Application 17/302,113 is a continuation of application No. 16/335,896, abandoned, previously published as PCT/CA2017/051120, filed on Sep. 9, 2017.
Claims priority of provisional application 62/398,797, filed on Sep. 23, 2016.
Claims priority of provisional application 62/398,819, filed on Sep. 23, 2016.
Claims priority of provisional application 62/398,183, filed on Sep. 22, 2016.
Prior Publication US 2022/0098594 A1, Mar. 31, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/68 (2017.01); A61K 31/155 (2006.01); A61K 31/7088 (2006.01); A61K 38/17 (2006.01); A61P 3/04 (2006.01); C07K 16/28 (2006.01); C12N 15/113 (2010.01); C12N 15/62 (2006.01)
CPC C12N 15/1138 (2013.01) [A61K 31/155 (2013.01); A61K 31/7088 (2013.01); A61K 38/179 (2013.01); A61P 3/04 (2018.01); C07K 16/2863 (2013.01); C07K 2319/30 (2013.01); C12N 2310/111 (2013.01); C12N 2310/122 (2013.01); C12N 2310/531 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A method for treating a disease or condition associated with premature senescence of retinal neurons in a subject in need thereof comprising administering to the subject an effective amount of
(i) a soluble Neuropilin-1 (NRP1) polypeptide that binds Semaphorin 3A (SEMA3A), wherein the soluble NRP1 polypeptide consists of an amino acid sequence having at least 95% identity with SEQ ID NO:82 and does not comprise the b2 and c domains of native human NRP1, or
(ii) a fusion protein comprising a soluble NRP1 polypeptide consisting of an amino acid sequence having at least 95% identity with SEQ ID NO:82 and that does not comprise the b2 and c domains of native human NRP1, fused to a fragment crystallizable (Fc) domain, and wherein said disease or condition associated with premature senescence of retinal neurons is glaucoma.